An interventional study of blood sample in Asthma Acute, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 296 studies in Asthma with a site in France — 44 open to participants now, 57 under way, 8 of them phase 3. Asthma · France.
Among the 296 studies in Asthma with a site in France, this one is the 60th largest by planned enrollment of the 204 interventional ones that give a count, is one of 25 that started in 2023, is one of 63 with no phase, reaches primary completion later than 41 of the 56 other live ones, and was the 256th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →44 of the 296 studies in Asthma with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, Argentina, Germany and 7 more countries
Ages 12–17
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
AstraZeneca · Sites in France, United States, Argentina and 11 more countries
Ages 6+
Sanofi · Sites in France, United States, Canada and 3 more countries
Ages 6+
University Hospital, Montpellier · Sites in France
Ages 8–12
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
296 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 25 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 448 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 209 across the 204 interventional studies, 137 across the 92 observational. Of the 221 that completed or were terminated, 85 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 296 have an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
10 of the studies in Asthma with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06988358University Hospital, RouenEarly Identification of Children With Asthma | 2026-12-31 |
| NCT05734261University Hospital, MontpellierForced Oscillations Technique During a Metacholine Test in Children | 2027-02-06 |
| NCT04763447Assistance Publique - Hôpitaux de ParisShort Treatment with Omalizumab for Severe Asthma | 2027-05-20 |
Add all 10 to your calendar (.ics) → With an account.
Among the 296 studies in Asthma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Asthma is a common chronic bronchial disease affecting 300 million people worldwide. The disease can be severe when it is not managed properly or when it is not controlled by treatments. Asthma is characterized by bronchial inflammation, bronchial hyperreactivity and tissue remodeling. Symptoms include episodes of coughing, dyspnoea and wheezing in relation with bronchial obstruction. The evolution is marked by the occurrence of exacerbations (increase of symptoms), most often triggered by viral infections, mostly due to rhinoviruses. The treatment of asthma is based on inhaled corticosteroid therapy sometimes combined with other treatments that help control the majority of asthma. However, about 10% of patients suffer from persistent symptoms despite these treatments.
Natural killer (NK) cells are important actors of the antiviral innate immune response and are present in high numbers in the lungs. However, their role in severe asthma and its virus-induced exacerbations is unknown.
The purpose of this work is to characterize NK cells in severe asthma in order to identify molecules expressed differently from control subjects. The goal is to assess whether these molecules could be potential biomarkers of a severe asthma subtype, also known as the endotype, and/or be the molecular control for exacerbation. The advantage of identifying biomarkers for inflammatory diseases lies in their usefulness in establishing a correct diagnosis, monitoring the progress of the disease and the effectiveness of treatments. The secondary objectives are to characterize the activation of NK cells in response to in vitro rhinovirus infection of different types, in monoculture or in a model of interaction with a bronchial epithelium, and identify one or more molecules involved in the interaction between bronchial epithelial cells and NK cells.
Inclusion Criteria:
Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:
Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation:
- Diagnosis of severe asthma confirmed by a respirologist at an expert centre
Case asthma controlled:
- Asthma control confirmed by a lung specialist from an expert centre
Case uncontrolled asthma excluding exacerbation:
- Uncontrolled asthma confirmed by a lung specialist from an expert centre
Case uncontrolled asthma with exacerbation:
- Current exacerbation
Exclusion Criteria:
Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:
Case patient with asthma:
- Coexistence of a chronic inflammatory disease other than asthma
Case healthy volunteers:
- Coexistence of an inflammatory pathology
Exclusion criteria:
Cases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU/L (measured on the study sample)
Biological: blood sample
Biological: blood sample
Biological: blood sample
Biological: blood sample
Blood sample (56mL) taken in a heparin tube
Changes in expression of one or more molecules on the surface of NK cells
Rationale for choice of primary endpoint: Our aim is to phenotype NK cells in different groups of severe asthma patients compared with control subjects, in order to identify at least one marker of disease discrimination on these cells. We are therefore looking for previously unknown changes in the expression of one or more molecules.
Time frame: day 1 to day 2555
Measurement of NK cell activation
Change From Baseline in the expression of CD107, CD69 and interferon-ɣ.
Time frame: day 1 to day 2555
Measurement of NK cell-induced epithelial cell activation and viability
Change From Baseline in epithelial cell cohesion, mucin and cytokine (IL-8, type I interferon, IL-33 and TSLP) production
Time frame: day 1 to day 2555
Started Sep 2023 (actual). Primary completion is estimated for Sep 2028, 60 months after the start.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 60 months is above that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →